mUC	Metastatic urothelial carcinoma
aUC	Advanced urothelial carcinoma
ICIs	Immune checkpoint inhibitors
PPIs	Proton pump inhibitors
PD-1	Programmed cell death protein 1
PD-L1	Programmed cell death-ligand 1
ECOG	Eastern Cooperative Oncology Group
NLR	Neutrophil-to-lymphocyte ratio
SII	Systemic immune-inflammation index
LDH	Lactate dehydrogenase
FDA	U.S. Food and Drug Administration
PS	Performance status
OS	Overall survival
ORR	Overall response rate
UC	Urothelial carcinoma
PFS	Progression free survival
LM	Metastases
Hb	Hemoglobin
TFPC	Time from prior chemotherapy
BMI	Body mass index
irAEs	Immune-mediated adverse events
DCR	Disease control rate
LN	lymph node
LH	luteinizing hormone
FSH	follicle-stimulating hormone
MLR	monocyte–lymphocyte ratio
PLR	platelet–lymphocyte ratio
CRP	C-reactive protein
MeSH	Medical subject headings
RT	Radiotherapy
MIBC	Muscle-invasive bladder cancer
AB	Antibiotics
DFS	Disease-free survival